|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003596,
umls-concept:C0022885,
umls-concept:C0030567,
umls-concept:C0030705,
umls-concept:C0037663,
umls-concept:C0039593,
umls-concept:C0114838,
umls-concept:C0871261,
umls-concept:C1167622,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-4-25
|
|
pubmed:abstractText |
Challenge with low-dose apomorphine causes a rise in growth hormone (GH) in patients with Parkinson's disease (PD). We studied 18 patients with early PD, who showed an increase of GH in the low-dose apomorphine test, by means of [(123)I] FP-CIT-SPECT. The mean specific dopamine transporter binding of the 18 patients was 1.50 +/- 0.56 in the striatum, 1.20 +/- 0.59 in the putamen, and 1.76 +/- 0.59 in the caudate nucleus. The increase of GH (1.05 +/- 1.01 ng/ml at baseline to 9.46 +/- 6.36 ng/ml 45 min after apomorphine injection; p < 0.001) was significant. There was a significant negative correlation of the increase of GH with the mean specific dopamine transporter binding in all three regions (r between -0.490 and -0.587; p between 0.04 and 0.01). Challenge with low-dose apomorphine may therefore be used as an indirect tool to measure the extent of nigrostriatal neurodegeneration in early PD.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0300-9564
|
|
pubmed:author |
pubmed-author:BaierP CPC,
pubmed-author:HappeSS,
pubmed-author:HelmschmiedKK,
pubmed-author:KochWW,
pubmed-author:MellerJJ,
pubmed-author:PaulusWW,
pubmed-author:TatschKK,
pubmed-author:TingsTT,
pubmed-author:TrenkwalderCC,
pubmed-author:WelschJJ,
pubmed-author:WuttkeWW
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
114
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
589-94
|
|
pubmed:meshHeading |
pubmed-meshheading:17187291-Adult,
pubmed-meshheading:17187291-Aged,
pubmed-meshheading:17187291-Apomorphine,
pubmed-meshheading:17187291-Binding, Competitive,
pubmed-meshheading:17187291-Corpus Striatum,
pubmed-meshheading:17187291-Dopamine,
pubmed-meshheading:17187291-Dopamine Agonists,
pubmed-meshheading:17187291-Dopamine Plasma Membrane Transport Proteins,
pubmed-meshheading:17187291-Female,
pubmed-meshheading:17187291-Growth Hormone,
pubmed-meshheading:17187291-Humans,
pubmed-meshheading:17187291-Male,
pubmed-meshheading:17187291-Middle Aged,
pubmed-meshheading:17187291-Parkinson Disease,
pubmed-meshheading:17187291-Predictive Value of Tests,
pubmed-meshheading:17187291-Substantia Nigra,
pubmed-meshheading:17187291-Tomography, Emission-Computed, Single-Photon,
pubmed-meshheading:17187291-Tropanes
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease.
|
|
pubmed:affiliation |
Department of Clinical Neurophysiology, University of Göttingen, Göttingen, Germany. Svenja.Happe@klinikum-bremen-ost.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
